drugset
drugset / Trial / NCT06619314

A Study to Evaluate the Effect of Food, Formulation, and a Proton Pump Inhibitor (PPI) on Calderasib (MK-1084) in Healthy Adult Participants (MK-1084-003)

NCT06619314 ↗

Phase 1 Completed 56 enrolled Merck Sharp & Dohme LLC
RandomizedCrossoverOpen-labelBasic science

Summary

The purpose of this study is to evaluate the effect of food, formulation, and a PPI on the levels of calderasib in a person's body over time.

Timeline

Start
2023-09-20
Primary completion
2023-11-25
Completion
2023-11-25

Drugs

EvaluationDrugModalityDoseRoute
Subject Calderasib Unknown — Oral

Indications

No indication recorded.